Kyowa Pharmaceutical, Inc Company Profile

15:14 EST 11th December 2018 | BioPortfolio

From its foundation in 1949, Kyowa Hakko has been a global leader in the pharmaceutical industry. Today, Kyowa's expertise extends to the United States through Kyowa Pharmaceutical, Inc. headquartered in Princeton, New Jersey.


212 Carnegie CenterSuite 101
New Jersey
United States of America


Phone: 609-919-1100
Fax: 609-919-1111

News Articles [288 Associated News Articles listed on BioPortfolio]

Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita

Ultragenyx Pharmaceutical (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, Kyowa Hakko Kirin and Kyowa Kirin In...

FDA approves Kyowa Kirin’s Poteligeo to treat two lymphoma types

The US Food and Drug Administration (FDA) has granted approval to biotechnology company Kyowa Kirin’s Poteligeo (mogamulizumab-kpkc) injection to treat...Read More... The post FDA approves Kyowa...

Kyowa Kirin gibt positive Stellungnahme des CHMP zu Mogamulizumab zur Behandlung von Mycosis fungoides und Sézary-Syndrom bekannt

Tokio (ots/PRNewswire) - Mogamulizumab wäre nach Zulassung der erste biologische Wirkstoff gegen CCR4 für Patienten in Europa. Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin), hat heute bekanntgegeben, ....

Kyowa Hakko Kirin Announces FDA Notification of PDUFA Action Date Extension for Mogamulizumab

Tokyo, Japan, May 30, 2018 –Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151 President and COO: Masashi Miyamoto, “Kyowa Hakko Kirin”) announced today that it has been notified that the U.S. Food and Dr...

Kyowa Kirin Announces POTELIGEO® Receives Marketing Authorisation in Europe for the Treatment of Mycosis Fungoides and Sézary Syndrome

Tokyo (ots/PRNewswire) - POTELIGEO will be the first biologic agent targeting CCR4 to be available for patients in Europe. Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces today that it has rec...

EU approves Kyowa Kirin's drug for rare lymphoma

The European Commission has approved Poteligeo (mogamulizumab), a treatment for rare types of non-Hodgkin’s lymphoma. The drug is manufactured by Japanese firm Kyowa Hakko Kirin (Kyowa Kirin), and ...

Priority review voucher sold by Ultragenyx, Kyowa

A rare pediatric disease priority review voucher was sold by Ultragenyx Pharmaceutical and Kyowa Hakko Kirin to an undisclose -More- 

FDA Approves Kyowa Kirin’s Poteligeo for Treatment of Two Rare Types of Non-Hodgkin Lymphoma

TOKYO, Aug. 8, 2018 /PRNewswire/ — Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces today that the U.S. Food and Drug Administration (FDA) has granted approval for Poteligeo® (mogamulizumab...

PubMed Articles [505 Associated PubMed Articles listed on BioPortfolio]

Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates.

Within (European) healthcare systems, the predominant goal for pharmaceutical expenditure is cost containment. This is due to a general belief among healthcare policy makers that pharmaceutical expend...

Applications of various analytical techniques in quality control of pharmaceutical excipients.

Although excipients are pharmacologically inert substances, still they are integral and significant ingredients of a pharmaceutical formulation. Their amount and concentration level along with the act...

Applications of proteomics in pharmaceutical research and development.

The significance of proteomics in the pharmaceutical industry has increased since overcoming initial difficulties. This review discusses recent proteomics publications from pharmaceutical companies to...

Solid-state insight into the action of a pharmaceutical solvate: structural, thermal and dissolution analysis of indinavir sulfate ethanolate.

The crystal structure of indinavir sulfate, a pharmaceutical administered as an ethanol solvate, is presented, revealing a unique channel/ionic solvate structure to be characteristic of the compound. ...

Comparison of Rheological and Sedimentation Behavior of Commercially Available Suspending Vehicles for Oral Pharmaceutical Preparations.

A pharmaceutical suspension is a semi-liquid dosage form suitable for patients being unable to swallow solid medicines such as tablets and capsules. A vehicle used for the preparation of pharmaceutica...

Clinical Trials [331 Associated Clinical Trials listed on BioPortfolio]

Clinical Impact of Pharmaceutical Consultations in Patients Treated for Chronic Obstructive Pulmonary Disease at Home

The implementation of pharmaceutical consultations in the city or at the hospital could modify the occurrence of exacerbations related to chronic obstructive pulmonary disease after return...

Pharmaceutical Care for Asthma Control Improvement (PHARMACI)-Study

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for asthma patients.

Pharmaceutical Care for Diabetes Type 2 Patients: a Randomised Controlled Trial

The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for diabetes type 2 patients. Patients will be randomly allocated to th...

Improving Compliance Among Elderly Polypharmacy Users Through Community Pharmacy Based Pharmaceutical Care Program

The aim of the project is to evaluate effectiveness of a multidimensional pharmaceutical care plan in improving compliance among elderly polypharmacy users at community pharmacy settings. ...

Impact of Collaborative Pharmaceutical Care on Hospital Admission Drug Prescriptions for Patients 65 Years of Age and Older

The primary objective of this study is to evaluate the impact of the implementation of collaborative pharmaceutical care on drug support at admission for patients 65 years of age and older...

Companies [1056 Associated Companies listed on BioPortfolio]

Kyowa Pharmaceutical, Inc

From its foundation in 1949, Kyowa Hakko has been a global leader in the pharmaceutical industry. Today, Kyowa's expertise extends to the United States through Kyowa Pharmaceutical, Inc. headquartered...

Kyowa Hakko, USA Inc.

Kyowa Hakko

Kyowa Hakko USA

Kyowa Hakko Kirin Co. Ltd.

More Information about "Kyowa Pharmaceutical, Inc" on BioPortfolio

We have published hundreds of Kyowa Pharmaceutical, Inc news stories on BioPortfolio along with dozens of Kyowa Pharmaceutical, Inc Clinical Trials and PubMed Articles about Kyowa Pharmaceutical, Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Kyowa Pharmaceutical, Inc Companies in our database. You can also find out about relevant Kyowa Pharmaceutical, Inc Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record